Pfizer

Strategic intent

Pfizer is a global biopharmaceutical company that discovers, develops, manufactures, and commercializes a wide range of medicines and vaccines for human health across multiple therapeutic areas.

Key market signals

• 2025-11: Completed the acquisition of Metsera, a clinical-stage biopharmaceutical company focused on obesity and cardiometabolic diseases, for an enterprise value of approximately $7.0 billion plus potential milestone payments.
• 2025-09: Announced the acquisition of Metsera for up to $10 billion, signaling a major strategic entry into the high-growth obesity treatment market after a bidding war.
• 2025-01: Appointed Chris Boshoff, MD, PhD, as the new Chief Scientific Officer and President of Research & Development, succeeding Mikael Dolsten, to lead a more focused R&D strategy.
• 2024-12: Received accelerated FDA approval for the Braftovi combination regimen as a first-line treatment for BRAF V600E-mutant metastatic colorectal cancer, which was converted to full approval in February 2026.
• 2024-05: Agreed to settle over 10,000 lawsuits alleging a link between the heartburn drug Zantac and cancer, part of a series of ongoing settlements to manage significant legal risk.

Financial health

• 2025 Full-Year Revenue: $62.6 billion, a 2% operational decline from the previous year, though revenues excluding COVID-19 products grew 6% operationally.
• 2026 Full-Year Revenue Forecast: Between $59.5 billion and $62.5 billion.
• 2026 Adjusted Diluted EPS Forecast: Between $2.80 and $3.00 per share.

Impact & compliance

Legal & risks

Within the last 24 months, Pfizer has faced significant legal challenges. In January 2025, on behalf of its subsidiary Biohaven, Pfizer agreed to pay nearly $60 million to resolve allegations of paying kickbacks to induce prescriptions for the migraine drug Nurtec ODT prior to its acquisition. In No

Classifications

🔒 Proprietary analysis

Proprietary Analysis — available with full access

Want the full analysis?

Get access to strategic fit scoring, cultural fit analysis, full forensic detail, and alignment dimensions.